In fact, KIR-HLA mismatch in the graft-versus-host direction may protect allogeneic HSCT recipients against the development of GVHD, possibly through elimination of host antigen-presenting dendritic cells and alloreactive GVHD-mediating T cells [2,34,35]. The gene discussed is KIR3DL1; the disease is graft versus host disease.